Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Bayer's sevabertinib wins NMPA approval as first-line therapy for HER2-mutant non-small cell lung cancer based on Ph1/Ph2 data
Small molecule, cancer, tyrosine kinase inhibitor, non-small cell lung cancer, HER2 - Read more

Boehringer Ingelheim, Sino Biopharmaceutical partner on six oncology biologics, $358M upfront, $7B milestones
Co-development, oncology, antibody-drug conjugate, milestone payments, royalties - Read more

Blackstone Life Sciences, Boston Scientific co-fund next-generation miniature heart pump development in $455M deal
Co-development, cardiovascular, medical devices, milestone payments - Read more

Minghui Pharmaceutical licenses TED candidate MHB018A to ASKA Pharmaceutical for Japan, $440M deal, $110M upfront
Licensing deal, autoimmune, antibody, milestone payments, royalties - Read more

Exogenus Therapeutics leads €13M($14.6M) EU consortium to advance secretome therapy EXO-101 for osteoarthritis
Research collaboration, regenerative medicine, extracellular vesicles, osteoarthritis, GMP manufacturing, clinical development - Read more

AbbVie licenses Nxera Pharma's IBD EP4 agonist NXE0033744 for $100M upfront, up to $1.47B total
Licensing deal, autoimmune, small molecule, milestone payments, royalties - Read more

CStone Pharmaceuticals, Kimia Therapeutics collaborate on clinical development of first-in-class DDR pathway solid tumor candidate
Clinical collaboration, oncology, small molecule, AI/ML, milestone payments, royalties - Read more

Science 2 Sales is the outbound engine for companies selling into biotech & pharma. We handle the market intelligence, prospect scoring, email sequences, LinkedIn outreach, and cold calling - so your sales team inherits a full calendar of qualified meetings.

Built by biopharma BD & sales reps, exclusively for biopharma commercial teams. It’s the platform and service we wish we had years ago.

Learn more and book a free strategy call on our website.

Madrigal Pharmaceuticals' Rezdiffra surpasses $1.7B annualized sales, posts first quarterly profit
Small molecule, MASH, revenue impact, major transaction - Read more

Teva's branded neurology sales surge 33%, offsetting generic decline and prompting 2026 guidance raise
Small molecule, neurological, revenue impact, financial - Read more

Novo raises full-year outlook after oral Wegovy quarterly sales hit $812M, beating expectations
Small molecule, obesity, financial, competitive - Read more

Amgen raises full-year revenue outlook to $39.7B after Q3 beat driven by Repatha, Imdelltra
Small molecule, oncology, cardiovascular, revenue impact - Read more

nPhase raises $30M Series D to expand AI-native clinical data platform
Clinical data platform, AI/ML platform, CRO, clinical trials - Read more

Safi Biotherapeutics receives $4.7M non-dilutive award extension to develop cryopreserved red blood cell formulation
Cell therapy, stem cell-derived, transfusion medicine, sickle cell disease, biomanufacturing - Read more

Newleos Therapeutics receives $15.5M NIH grant to advance NTX-2001 for cocaine use disorder
Neuropsychiatric, small molecule, substance use disorders, clinical-stage - Read more

Vitroscope raises $7M in funding, advancing real-time immune activity and disease mechanism platform
Platform technology, live-cell imaging, organoids, preclinical, drug discovery - Read more

Thryv Therapeutics raises $30M Series B to launch ASPIRE-HF heart failure study
Clinical-stage, cardiovascular, rare disease, small molecule, inherited channelopathies - Read more

AbbVie invests £120M ($160M) in UK, launching new Oxford R&D site expanding immunology, neuroscience, oncology capabilities
Monoclonal antibody, immunology, oncology, major transaction - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Sanofi discontinues Nurix Therapeutics' STAT6 degrader SAR448272, citing molecule-specific nonclinical findings, not target issues
Licensing deal, autoimmune, small molecule, drug discovery, milestone payments - Read more

Servier's (sevasemten) fails Ph3 primary endpoint in patients with Becker muscular dystrophy
Small molecule, neuromuscular disease, fast skeletal myosin inhibitor, Becker muscular dystrophy, Duchenne muscular dystrophy - Read more

Madrigal Pharmaceuticals faces whistleblower lawsuit alleging Rezdiffra liver-injury data cover-up and clinical trial manipulation
Small molecule, metabolic disease, patient safety, data integrity - Read more

Ultragenyx cuts 20% workforce and halves R&D budget to $350M, targeting 2027 profitability
Rare disease, gene therapy, cost reduction, operational - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here